Celldex Therapeutics Inc

CLDX

29.470USD

-2.280-7.18%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

Celldex Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

58 / 391

Overall Ranking

166 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Celldex Therapeutics Inc Highlights

StrengthsRisks

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.54M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.54M.

Overvalued

The company’s latest PE is -7.78, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 73.56M shares, increasing 2.11% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 937.16K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.51.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

54.333

Target Price

+71.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Celldex Therapeutics Inc is 5.53, ranking 347 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 121.00K, representing a year-over-year decrease of 89.70%, while its net profit experienced a year-over-year decrease of 72.68%.

Score

Industry at a Glance

Previous score

5.53

Change

0



Financials

6.21

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.11

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Celldex Therapeutics Inc is 6.88, ranking 203 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.78, which is -28.08% below the recent high of -5.59 and -154.55% above the recent low of -19.80.

Score

Industry at a Glance

Previous score

6.88

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Celldex Therapeutics Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 53.00, with a high of 90.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Celldex Therapeutics Inc is 7.05, ranking 87 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 33.91 and the support level at 27.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.42

Change

-0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Celldex Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 131.89%, representing a quarter-over-quarter increase of 0.56%. The largest institutional shareholder is The Vanguard, holding a total of 4.01M shares, representing 6.03% of shares outstanding, with 2.99% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Wellington Management Company, LLP

7.39M

+27.50%

Kynam Capital Management LP

6.10M

--

BlackRock Institutional Trust Company, N.A.

4.55M

-0.72%

The Vanguard Group, Inc.

Star Investors

3.94M

-0.06%

Bellevue Asset Management AG

3.56M

-1.66%

State Street Investment Management (US)

2.84M

+18.15%

Fidelity Management & Research Company LLC

3.55M

-10.08%

Commodore Capital LP

3.03M

-12.22%

T. Rowe Price Associates, Inc.

Star Investors

2.31M

-38.52%

Deep Track Capital LP

2.00M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Celldex Therapeutics Inc is 6.08, ranking 29 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Celldex Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Celldex Therapeutics Inc

CLDX

7.03 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment